Prompt treatment of bradykinin-mediated angioedema by plasma derived C1-INH or icatibant remains a challenge for EMS.24 Our result underscores the potential efficacy of these drugs in ACEI-AAE and confirms the recently reported efficacy of icatibant in a phase 2 study13 and the efficacy of plasma-derived C1-INH in several clinical case reports.11,12 Plasma-derived C1-INH decreases bradykinin production. The gene discussed is SERPING1; the disease is acquired angioedema.